Genistein

Genistein at a Glance

Genistein is the principal isoflavone of soybean and the molecule most people mean when they say “plant oestrogen”. It binds both oestrogen receptors, with a marked preference for ERβ, and activates them at nanomolar concentrations — far weaker than oestradiol, but strong enough to have measurable effects in people ^{1Reference 1Kuiper GG et al. · 1998In vitroInteraction of estrogenic chemicals and phytoestrogens with estrogen receptor beta — in vitroView study →}. It takes its name from Genista, the broom genus it was first isolated from, but in practice almost all human exposure comes from soy, where it is stored as the glucoside genistin and freed by gut enzymes after eating ^{16,17Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →Reference 17Setchell KD et al. · 2002Clinical trialEvidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability — clinical trialView study →}.

What sets genistein apart from most phytochemicals is that the isolated molecule has been through real clinical trials. A single 54 mg/day regimen of genistein aglycone was tested in Italian postmenopausal women for bone loss, hot flushes, endothelial function and metabolic syndrome, in randomised placebo-controlled studies running one to three years ^{5,6,7,9,10Reference 5Marini H et al. · 2007RCTEffects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial — randomised controlled trialView study →Reference 6Marini H et al. · 2008RCTBreast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study — randomised controlled trialView study →Reference 7Crisafulli A et al. · 2004RCTEffects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study — randomised controlled trialView study →Reference 9Squadrito F et al. · 2003RCTEffect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study — randomised controlled trialView study →Reference 10Squadrito F et al. · 2013RCTGenistein in the metabolic syndrome: results of a randomized clinical trial — randomised controlled trialView study →}. That leaves an unusual amount of human data — and an unusually clear picture of where the molecule stops.

The rest of its reputation comes from the laboratory, where genistein is a standard research reagent: a tyrosine-kinase inhibitor, a topoisomerase-II poison and an activator of the CFTR chloride channel ^{2,3,4Reference 2Akiyama T et al. · 1987In vitroGenistein, a specific inhibitor of tyrosine-specific protein kinases — in vitroView study →Reference 3Markovits J et al. · 1989In vitroInhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II — in vitroView study →Reference 4Illek B et al. · 1995In vitrocAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein — in vitroView study →}. Those effects are real, but they appear at concentrations tens to hundreds of times higher than a diet or supplement produces in blood. Keeping the two concentration regimes apart is the whole art of reading genistein research.

Two Molecules at Two Concentrations

Genistein behaves like two different compounds depending on how much of it is present, and most confusion about it comes from mixing the two.

At nanomolar concentrations — the range a soy meal or a 54 mg tablet produces in plasma — genistein is a phytoestrogen. It competes with oestradiol for both receptor subtypes, binds ERβ more strongly than ERα, and switches on oestrogen-responsive genes at 1–10 nM; in the transactivation assay it ranked with coumestrol as the most potent dietary phytoestrogen at ERβ and behind only zearalenone and coumestrol at ERα ^{1Reference 1Kuiper GG et al. · 1998In vitroInteraction of estrogenic chemicals and phytoestrogens with estrogen receptor beta — in vitroView study →}. Every human trial of genistein is a test of this low-concentration molecule.

At micromolar concentrations — 10 to 100 µM, typical of cell-culture experiments — genistein becomes something else. In 1987 it was identified as a specific inhibitor of tyrosine-specific protein kinases, competitive with ATP, sparing serine/threonine kinases such as protein kinase A and protein kinase C ^{2Reference 2Akiyama T et al. · 1987In vitroGenistein, a specific inhibitor of tyrosine-specific protein kinases — in vitroView study →}. Two years later it was shown to inhibit mammalian DNA topoisomerase II, stabilising the enzyme’s cleavable complex and producing protein-linked DNA strand breaks without intercalating into DNA ^{3Reference 3Markovits J et al. · 1989In vitroInhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II — in vitroView study →}. It also activates the cystic-fibrosis chloride channel CFTR through a cAMP-independent route ^{4Reference 4Illek B et al. · 1995In vitrocAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein — in vitroView study →}. These three findings made genistein a laboratory workhorse, and they underlie most of the “anticancer” cell-line literature.

The gap between the two regimes matters because oral genistein reaches a terminal plasma half-life of about 3.8 hours for the free aglycone, and even single doses of 16 mg/kg — far above any supplement — produce peak plasma levels that mostly remain below the micromolar range where the kinase and topoisomerase effects begin ^{18Reference 18Bloedon LT et al. · 2002RCTSafety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women — randomised controlled trialView study →}. So a cell-culture result at 50 µM says almost nothing about what a soy diet does, and a human trial at 54 mg/day says almost nothing about kinase inhibition. The two belong in separate columns.

Genistein & Its Relatives

Genistein sits at the centre of a small family of legume isoflavones that convert into one another.

• Genistin is genistein 7-O-glucoside, the form in which soy stores it. The glucoside is not absorbed intact — sensitive mass spectrometry finds no trace of it in plasma after ingestion — and must first be hydrolysed by intestinal β-glucosidases, which delays but does not reduce absorption ^{17Reference 17Setchell KD et al. · 2002Clinical trialEvidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability — clinical trialView study →}.
• Biochanin A is genistein’s 4’-methyl ether and the dominant isoflavone of red clover. It is rapidly and efficiently demethylated in the body, so red-clover extracts produce high plasma genistein even though the herb itself carries only traces of it ^{16Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →}.
• Daidzein is the 5-deoxy sibling, always alongside genistein in soy. Given equal doses, plasma genistein runs consistently higher than daidzein because daidzein distributes more widely into tissue (236 L versus 161 L apparent volume) ^{16Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →}.
• Formononetin is daidzein’s methyl ether, the second red-clover isoflavone, and follows the same demethylation route.

The practical consequence is that the human isoflavone literature is often about genistein whether or not the trial used it. A red-clover or soy-germ supplement is, after first-pass metabolism, largely a genistein-and-daidzein delivery system ^{16Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →}.

An Inactive Partner in Maconha Brava

One of genistein’s more unusual appearances is in maconha brava (Zornia latifolia), a South American legume sold as a cannabis substitute. When a lipophilic leaf extract was tested on cultured rat cortical neurons by multielectrode array, it suppressed mean firing and bursting rates in a way the authors compared to high-THC hashish. The most active fraction was dominated by genistein and apigenin in roughly a 1:1 ratio, with the rare flavone syzalterin as a minor component ^{30Reference 30Alloisio S et al. · 2022In vitroCannabis-like activity of Zornia latifolia Sm. detected in vitro on rat cortical neurons: major role of the flavone syzalterin — in vitroView study →}.

Genistein was not the active principle. Pure genistein and pure apigenin standards did not reproduce the inhibition; pure syzalterin did, and so did a 1:9 mixture of syzalterin and genistein — the ratio in the plant fraction — suggesting genistein at most potentiates or carries the syzalterin effect ^{30Reference 30Alloisio S et al. · 2022In vitroCannabis-like activity of Zornia latifolia Sm. detected in vitro on rat cortical neurons: major role of the flavone syzalterin — in vitroView study →}. It is a single in-vitro dataset with no animal or human follow-up, but it is a clean demonstration that the most abundant flavonoid in a plant is not necessarily the one doing the work.

What It's Used For

Genistein has more isolated-molecule human trials than almost any other plant phenolic, nearly all from one research group in Messina using 54 mg/day of genistein aglycone, plus the wider soy-isoflavone literature in which genistein is the dominant active. The rows below distinguish trials of the isolate from trials of isoflavone mixtures.

Mechanisms

The oestrogen-receptor row explains the human trials; the kinase and topoisomerase rows explain the cell-culture literature. They do not overlap in concentration, and that separation is the key to reading the evidence.

Pharmacokinetics

Genistein is well absorbed, but its form matters. Soy delivers it almost entirely as the glucoside genistin, which is not absorbed intact and must be hydrolysed in the gut; peak plasma levels arrive at about 5.2 hours for the aglycone and 9.3 hours for the glucoside, with the glucoside actually giving the larger area under the curve ^{16,17Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →Reference 17Setchell KD et al. · 2002Clinical trialEvidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability — clinical trialView study →}. Genistein’s apparent volume of distribution (161 L) confirms extensive tissue distribution, and plasma genistein runs consistently higher than daidzein at equal doses ^{16Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →}. In a single-dose study of 2–16 mg/kg in postmenopausal women, the terminal half-life of free genistein averaged 3.8 hours and of total (conjugated plus free) genistein about 10 hours, a profile the authors judged unlikely to accumulate with twice-daily dosing ^{18Reference 18Bloedon LT et al. · 2002RCTSafety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women — randomised controlled trialView study →}. Most circulating genistein is conjugated as glucuronides and sulfates; the free aglycone is a minority fraction, which is another reason micromolar cell-culture effects overstate systemic exposure. It is a native substrate of the efflux transporter ABCG2 (BCRP), which shapes both its own disposition and its interaction potential ^{15Reference 15Imai Y et al. · 2004In vitroPhytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance — in vitroView study →}.

Clinical Trials

Genistein aglycone at 54 mg/day has completed randomised trials of 12 to 36 months for bone density, hot flushes, endothelial function and metabolic syndrome, all from one Italian group ^{5,6,7,9,10Reference 5Marini H et al. · 2007RCTEffects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial — randomised controlled trialView study →Reference 6Marini H et al. · 2008RCTBreast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study — randomised controlled trialView study →Reference 7Crisafulli A et al. · 2004RCTEffects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study — randomised controlled trialView study →Reference 9Squadrito F et al. · 2003RCTEffect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study — randomised controlled trialView study →Reference 10Squadrito F et al. · 2013RCTGenistein in the metabolic syndrome: results of a randomized clinical trial — randomised controlled trialView study →}; short-term phase-2 work exists in prostate cancer ^{12Reference 12Lazarevic B et al. · 2011RCTEfficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial — randomised controlled trialView study →}; and two trials in Sanfilippo syndrome were negative on clinical endpoints ^{13,14Reference 13de Ruijter J et al. · 2012RCTGenistein in Sanfilippo disease: a randomized controlled crossover trial — randomised controlled trialView study →Reference 14Ghosh A et al. · 2021RCTHigh dose genistein in Sanfilippo syndrome: A randomised controlled trial — randomised controlled trialView study →}.

Last checked: September 2026.

Isolate vs. Plant Studies

Genistein inverts the usual complaint about plant constituents: the human evidence is mostly for the isolate. The Messina trials used purified genistein aglycone in tablets ^{5,6,7,9,10Reference 5Marini H et al. · 2007RCTEffects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial — randomised controlled trialView study →Reference 6Marini H et al. · 2008RCTBreast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study — randomised controlled trialView study →Reference 7Crisafulli A et al. · 2004RCTEffects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study — randomised controlled trialView study →Reference 9Squadrito F et al. · 2003RCTEffect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study — randomised controlled trialView study →Reference 10Squadrito F et al. · 2013RCTGenistein in the metabolic syndrome: results of a randomized clinical trial — randomised controlled trialView study →}, the prostate trial used synthetic genistein ^{12Reference 12Lazarevic B et al. · 2011RCTEfficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial — randomised controlled trialView study →}, and the Sanfilippo trials used a genistein-rich extract and then pure aglycone ^{13,14Reference 13de Ruijter J et al. · 2012RCTGenistein in Sanfilippo disease: a randomized controlled crossover trial — randomised controlled trialView study →Reference 14Ghosh A et al. · 2021RCTHigh dose genistein in Sanfilippo syndrome: A randomised controlled trial — randomised controlled trialView study →}. Where mixtures were tested — the soy-isoflavone hot-flush meta-analysis, the ⁴¹Ca bone study — the effect tracked genistein content, with higher-genistein supplements outperforming lower ones ^{8,11Reference 8Taku K et al. · 2012Meta-analysisExtracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials — meta-analysisView study →Reference 11Weaver CM et al. · 2009RCTAntiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology — randomised controlled trialView study →}.

What transfers back to the plants is less clear. Soy foods deliver genistein as genistin alongside daidzin and glycitin at doses that vary enormously between products ^{31Reference 31Murphy PA et al. · 1999Isoflavones in retail and institutional soy foods — analyticalView study →}; red clover, broom and wild indigo carry it only as a trace or as its methylated precursor ^{16Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →}; and in maconha brava it is abundant but pharmacologically inert on the endpoint that matters ^{30Reference 30Alloisio S et al. · 2022In vitroCannabis-like activity of Zornia latifolia Sm. detected in vitro on rat cortical neurons: major role of the flavone syzalterin — in vitroView study →}. Genistein is therefore best understood as a supplement molecule that also occurs in herbs, rather than the reverse.

Its Role in Plants

Genistein is made from the flavanone naringenin by isoflavone synthase, a cytochrome-P450 enzyme that performs an unusual aryl-ring migration; the gene is essentially confined to legumes, which is why isoflavones are a Fabaceae signature and why engineering the enzyme into non-legumes lets them make genistein ^{29Reference 29Dixon RA · 2002ReviewGenistein — reviewView study →}. In the plant it is a branch-point compound — the precursor of the antimicrobial phytoalexins and phytoanticipins that legumes deploy against pathogens ^{29Reference 29Dixon RA · 2002ReviewGenistein — reviewView study →}.

Its most elegant job is below ground. Soybean roots exude genistein and daidzein, and these two isoflavones were identified in 1987 as the signals that induce the common nod genes of Bradyrhizobium japonicum, the bacterium that forms nitrogen-fixing nodules on soy. The signal is species-specific: the same isoflavones do not induce the nod genes of the clover symbiont, which answers to flavones instead ^{28Reference 28Kosslak RM et al. · 1987In vitroInduction of Bradyrhizobium japonicum common nod genes by isoflavones isolated from Glycine max — in vitroView study →}. Genistein is, in other words, part of how a soybean recruits its nitrogen supply.

Prevalence in Nature

Genistein is a legume isoflavone, and soybean is its dominant source by an order of magnitude. In soy it occurs almost entirely as the glucoside genistin and its acetyl and malonyl esters, with free genistein appearing on fermentation or processing. A national survey of retail soy foods found total isoflavones ranging from about 1 µg/g in soy sauce to 540 µg/g in tempeh, with soymilk and tofu the main dietary carriers — a 500-fold spread that makes “a serving of soy” an unreliable dose ^{31Reference 31Murphy PA et al. · 1999Isoflavones in retail and institutional soy foods — analyticalView study →}. Soy-based infant formulas contained 32–47 µg/mL total isoflavones, giving a formula-fed four-month-old roughly 4.5–8 mg/kg/day ^{26Reference 26Setchell KD et al. · 1997ObservationalExposure of infants to phyto-oestrogens from soy-based infant formula — observationalView study →}.

In red clover, native genistein is a trace component; the plant stores biochanin A, and genistein is generated after ingestion ^{16Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →}. Ordinary broom carries genistein and genistin as part of its flavonoid background, without published quantities, and dyer’s broom (Genista tinctoria) is the historical source. Wild indigo (Baptisia tinctoria) and shrubby bushclover (Lespedeza bicolor) report it qualitatively; in the bushclover it is one of the constituents behind an in-vitro oestrogenic signal. Maconha brava is the one non-soy source where it is a major leaf flavonoid, at roughly a 1:1 ratio with apigenin, though no absolute figure has been published ^{30Reference 30Alloisio S et al. · 2022In vitroCannabis-like activity of Zornia latifolia Sm. detected in vitro on rat cortical neurons: major role of the flavone syzalterin — in vitroView study →}. Kudzu, chickpea, lupin and fava bean carry it in smaller amounts, and it turns up outside the Fabaceae only sporadically.

Discovery & Synthesis

Genistein was first isolated in 1899 from dyer’s broom (Genista tinctoria), the plant whose genus name it carries, and identified in soybean in 1931. Chemically it is 4’,5,7-trihydroxyisoflavone, and it can be made by two classical routes — the deoxybenzoin route (cyclising a 2-hydroxy-deoxybenzoin with a one-carbon unit) and the chalcone route ^{29Reference 29Dixon RA · 2002ReviewGenistein — reviewView study →}. Its modern identity was set in the 1980s, when the discovery that it inhibits tyrosine kinases ^{2Reference 2Akiyama T et al. · 1987In vitroGenistein, a specific inhibitor of tyrosine-specific protein kinases — in vitroView study →} and topoisomerase II ^{3Reference 3Markovits J et al. · 1989In vitroInhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II — in vitroView study →} turned a legume pigment into a standard biochemical reagent, and in the 1990s, when its oestrogen-receptor pharmacology was mapped ^{1Reference 1Kuiper GG et al. · 1998In vitroInteraction of estrogenic chemicals and phytoestrogens with estrogen receptor beta — in vitroView study →}.

Manufacture today runs both ways. Research-grade and supplement genistein is either extracted from soy germ or soy-isolate by-products and hydrolysed from genistin, or made by chemical synthesis — the prostate trial used synthetic material ^{12Reference 12Lazarevic B et al. · 2011RCTEfficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial — randomised controlled trialView study →}, and the hot-flush meta-analysis included “extracted or synthesized” isoflavones without distinguishing them ^{8Reference 8Taku K et al. · 2012Meta-analysisExtracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials — meta-analysisView study →}. Recombinant isoflavone synthase now allows genistein production in engineered non-legume plants and microbes ^{29Reference 29Dixon RA · 2002ReviewGenistein — reviewView study →}.

Dosage

Almost all of the isolated-genistein human data rest on one regimen. These are doses studied in research and are not a personal recommendation.

Dietary exposure from soy foods is far more variable than any tablet — a 500-fold range of isoflavone content across products ^{31Reference 31Murphy PA et al. · 1999Isoflavones in retail and institutional soy foods — analyticalView study →} — and glucoside-rich foods deliver genistein more slowly but at least as completely as the aglycone ^{16,17Reference 16Setchell KD et al. · 2001Clinical trialBioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements — human studyView study →Reference 17Setchell KD et al. · 2002Clinical trialEvidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability — clinical trialView study →}.